Dudediligence.

Travere Therapeutics, Inc

TVTXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$62.9MSep ’24$74.8MDec ’24$81.7MMar ’25$114.4MJun ’25$164.9MSep ’25$129.7MDec ’25$127.2MMar ’26$169.6MJun ’26
Net income, by quarter
−$54.8MSep ’24−$60.3MDec ’24−$41.2MMar ’25−$12.8MJun ’25$25.7MSep ’25$2.7MDec ’25−$37.1MMar ’26−$34.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$131.8M$109.5M$145.2M$233.2M$490.7M
Gross profit$128.0M$105.0M$133.8M$225.4M$480.4M
Operating income−$199.4M−$319.8M−$388.1M−$323.8M−$62.8M
Net income−$180.1M−$278.5M−$111.4M−$321.5M−$25.5M
Operating cash flow−$14.8M−$186.3M−$280.0M−$237.5M$37.8M
Free cash flow−$19.9M−$186.5M−$280.7Mnone on filenone on file
Cash$165.8M$61.7M$58.2M$58.5M$93.0M
Shares outstanding62.5M64.3M75.4M87.5M90.9M